Nexalin Technology announces additional results in AD with Gen-2 SYNC device

Nexalin Technology (NXL) announced the publication of additional clinical data in Radiology demonstrating that its proprietary 15 milliamp Gen-2 Nexalin DIFS technology-Nexalin’s advanced implementation of transcranial alternating current stimulation-improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer’s disease, AD. Key Findings from the Clinical Study: Clinically Meaningful Cognitive Gains: Patients receiving Nexalin’s Gen-2 SYNC 40-Hz DIFS device showed a significant improvement in Mini-Mental State Examination scores and additional significant improvement in Montreal Cognitive Assessment scores compared to baseline. These improvements were statistically significant when compared to the sham group. Neuroimaging-Confirmed Mechanism: Resting-state functional MRI revealed enhanced functional connectivity between the hippocampus and key cortical regions. Network-Level Effects: Statistically significant increases in FC were also observed across broader cognitive networks, including the default mode network, frontoparietal networks, and visual and auditory systems. Correlated Cognitive Gains: Increased connectivity between the hippocampus and middle cingulate gyrus was significantly correlated with improvement on the Boston Naming Test. Excellent Safety Profile: No adverse events were reported during the treatment period, reinforcing the safety and tolerability of Nexalin’s DIFS technology.